Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

August 09, 2021

Data that were presented during the 2021 ASCO Annual Meeting shed light on new therapeutic strategies, and treatment considerations that are expanding the paradigms of gastrointestinal malignancies.

August 05, 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

August 05, 2021

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

August 05, 2021

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

August 04, 2021

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma. 

August 04, 2021

Chung-Han Lee, MD, PhD, discusses the goals of the phase 3 KEYNOTE-B61 study and the potential for immunotherapy/TKI combinations in non–clear cell RCC.

August 03, 2021

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

August 03, 2021

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

August 03, 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

August 03, 2021

Memorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, has launched MSKCC India to provide cancer patients in India with access to the institution’s world-renowned oncologists, research, clinical trials, and education.

July 31, 2021

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

July 28, 2021

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

July 27, 2021

Lindsey Roeker, MD, discusses the emerging role of minimal residual disease as a predictive end point in chronic lymphocytic leukemia.

July 25, 2021

The combination of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine with and without consolidative radiotherapy was found to have strong efficacy and favorable tolerability in patients with early-stage, unfavorable-risk, Hodgkin lymphoma.

July 22, 2021

Meghan Thompson, MD, discusses emerging treatment strategies with BTK inhibitors in chronic lymphocytic leukemia.

July 20, 2021

Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.

July 09, 2021

Robert J. Motzer, MD, discusses the efficacy and health-related quality of life benefits of lenvatinib/pembrolizumab in patients with advanced RCC, and projected where the regimen might fit into the treatment paradigm.

July 06, 2021

Michael J. Mauro, MD, discusses managing symptom burden in patients with myelofibrosis.

July 06, 2021

Paul K. Paik, MD, discusses the clinical implications of tepotinib on the non–small cell lung cancer armamentarium.

July 01, 2021

Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.